Calidi Biotherapeutics has demonstrated notable progress in its oncology research, reporting a reduced first quarter net loss of $5.0 million compared to $7.2 million in the previous year. The company's strategic advancements in cancer treatment include receiving FDA clearance for an investigational new drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy targeting solid tumors.
At the American Association for Cancer Research (AACR) conference, the company presented promising data on its Redtail platform, showcasing an innovative approach to delivering IL15 superagonist via an engineered oncolytic virus. This research represents a potentially significant development in cancer treatment, particularly for metastatic diseases.
Key leadership additions, including new CEO Dr. Eric Poma and Chief Medical Officer Dr. Guy Clifton, signal the company's commitment to advancing its systemic virotherapy technologies. Calidi's unique approach involves using potent stem cells to carry oncolytic viruses, with the potential to enhance cancer treatment efficacy and patient safety.
The company's platform aims to develop off-the-shelf, universal cell-based delivery systems designed to protect, amplify, and potentiate oncolytic viruses. This dual approach could offer innovative strategies for treating or potentially preventing metastatic cancer, representing a promising avenue in oncological research.
